2020 | 2019 | 2018

September 18 2020

Brii Biosciences Appoints Rogers Luo, Ankang Li To Leadership Positions

- Rogers Yongqing Luo, B.M., MBA, President of Brii Bio and General Manager for Greater China, will lead acceleration of Brii Bio’s China strategy and expand the company’s capabilities in access and partnerships
- Ankang Li, Ph.D., J.D., CFA, Brii Bio’s Chief Financial Officer, will lead all financial and corporate development functions


Mar 31, 2020

Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19

- Multiple highly potent, neutralizing antibodies already identified from convalesced patients
- First-in-human trials planned for third quarter this year


Mar 11, 2020

Brii Biosciences Provides Funding to Columbia University for Research on COVID-19 and Other Coronaviruses

- Brii Biosciences will provide funding and expertise in infectious disease treatment modalities for projects in development in Aaron Diamond AIDS Research Center and other Columbia Laboratories –


Dec 03, 2019

Brii Biosciences Expands Therapeutic Focus to Include Neurosciences with Addition of John Kraus, M.D., Ph.D.

- Dr. Kraus to lead newly-created Neurosciences Therapy Area
- Zhijian Chen, Ph.D., named Strategic Scientific Advisor


Nov 21, 2019

Brii Biosciences Expands Infectious Disease Pipeline

- Three partnerships focused on novel programs for treatment-resistant bacterial infections and diseases
- Company pipeline now includes up to 12 partnered assets, in addition to internal development programs
- Infectious disease focus will address disproportional unmet need in China and support global public health


Nov 14, 2019

VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection

- Novel recombinant, protein-based immuno-therapeutic for the treatment of chronic hepatitis B virus (HBV) infection
- Two-part, dose-escalation study expected to enroll up to 65 patients
- Initial data expected in H2 2020


Dec 11, 2018

WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced today a strategic collaboration with Brii Biosciences…


Dec 06, 2018

Brii Biosciences Builds Innovative Pipeline, Forges Public-Private Partnerships to Bring Novel Medicines to Chinese Patients

Brii Biosciences, a company committed to serving patients’ needs and improving public health in China, today announced several research collaborations that significantly advance its efforts to develop innovative medicines to meet the unique needs of patients in China.


Oct 02, 2018

FierceBiotech names Brii Biosciences as one of its “Fierce 15” Biotech Companies of 2018

Beijing, China – October 2, 2018 – Brii Biosciences today was named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.


May 24, 2018

Brii Biosciences Launches to Bring Innovative Medicines to Chinese Patients

Brii Bio aims to accelerate the development and delivery of breakthrough medicines in China through partnerships, best-in-class research and development, and the disruptive application of digital and data insight.